Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis

Stephen Hough, Brynne Ascott-Evans, Tobie de Villiers, Jan de Weerd, Graham Ellis, Stan Lipschitz

Abstract


The mainstay of current therapies for osteoporosis is
antiresorptive agents such as calcium, vitamin D, oestrogen, selective oestrogen receptor modulators (SERMs), calcitonin and the bisphosphonates. These drugs reduce but do not eliminate fracture risk, and do not restore lost bone structure. Anabolic agents have the potential to increase bone mineral density (BMD), restore skeletal micro-architecture and reduce fracture risk to a greater extent than the antiresorptives.

Full Text: PDF


This journal is hosted by: OpenJournals Publishing. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License